Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression
M Prendecki, C Clarke, H Edwards, S McIntyre… - Annals of the rheumatic …, 2021 - Elsevier
Objective There is an urgent need to assess the impact of immunosuppressive therapies on
the immunogenicity and efficacy of SARS-CoV-2 vaccination. Methods Serological and T-
cell ELISpot assays were used to assess the response to first-dose and second-dose SARS-
CoV-2 vaccine (with either BNT162b2 mRNA or ChAdOx1 nCoV-19 vaccines) in 140
participants receiving immunosuppression for autoimmune rheumatic and glomerular
diseases. Results Following first-dose vaccine, 28.6%(34/119) of infection-naïve participants …
the immunogenicity and efficacy of SARS-CoV-2 vaccination. Methods Serological and T-
cell ELISpot assays were used to assess the response to first-dose and second-dose SARS-
CoV-2 vaccine (with either BNT162b2 mRNA or ChAdOx1 nCoV-19 vaccines) in 140
participants receiving immunosuppression for autoimmune rheumatic and glomerular
diseases. Results Following first-dose vaccine, 28.6%(34/119) of infection-naïve participants …